WRN and breast cancer: Specifically, the 1367Arg variant may affect the binding of p53 and/or BRCA1 to RECQL2, thus subtly compromising their function and leading to a weak phenocopy of BRCA1 and TP53 mutations, namely increased breast cancer risk and a younger age at onset.